That’s the key idea put forth in preliminary research posted this month to bioRxiv, authored by GSC, UBC and BC Children's Hospital Research Institute scientists, that highlights the potential benefits of testing COVID-19 patients for genetic variants of ACE2—the protein identified as the point-of-entry for the SARS-COV-2 virus into human cells.
As part of a federal funding announcement earlier today, Canada’s Michael Smith Genome Sciences Centre (GSC) at BC Cancer will be one of four Canadian institutions on the forefront of using genome science to understand how different people respond to COVID-19 infection.
Scientists reveal key insights into drug resistance in patients with del(5q) myelodysplastic syndrome
From fighting marine contaminants to fishing for cancer treatments from marine sponges: how a GSC biochemist made a drug discovery breakthrough
We all have a responsibility to take precautionary measures in order to help stop the global transmission of COVID-19. The GSC is helping our employees to find ways to attend work safely, including working remotely. We are also moving in-person gatherings to virtual interactions, and all tours of our facilities have been cancelled until further notice. For now, we will continue to accept and sequence samples and maintain all functionality including database and analytical capacities, prioritizing clinical and Personalized OncoGenomics pipelines.